Boothbay Fund Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Boothbay Fund Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,725	Closed	-$704K	–	2439
2026 Q1	$704K	Sell	3,725 -41,842	-92%	-$7.31M	0.01%	1150
2025 Q4	$7.75M	Buy	45,567 +17,720	+64%	+$2.72M	0.12%	185
2025 Q3	$3.67M	Buy	27,847 +11,526	+71%	+$1.38M	0.05%	407
2025 Q2	$1.73M	Buy	16,321 +4,000	+32%	+$435K	0.03%	536
2025 Q1	$1.53M	Buy	+12,321	New	+$1.61M	0.04%	495
2021 Q4	–	Sell	-19,632	Closed	-$2.56M	–	2039
2021 Q3	$2.56M	Buy	19,632 +7,487	+62%	+$1.13M	0.07%	358
2021 Q2	$2.16M	Buy	+12,145	New	+$2.1M	0.07%	354
2021 Q1	–	Sell	-2,513	Closed	-$414K	–	1655
2020 Q4	$415K	Buy	+2,513	New	+$374K	0.02%	822
2018 Q2	–	Sell	-3,005	Closed	-$454K	–	819
2018 Q1	$454K	Buy	+3,005	New	+$441K	0.05%	349

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Boothbay Fund Management's JAZZ Position: Q2 2026 in Review

Boothbay Fund Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 3,725 shares — an estimated $704K sold.

Boothbay Fund Management first reported a position in JAZZ in Q1 2018 and held it in 9 quarters. The position peaked at $7.75M in Q4 2025. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Boothbay Fund Management reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Boothbay Fund Management sold 3,725 Jazz Pharmaceuticals shares in Q2 2026, an estimated $704K.
Boothbay Fund Management first reported a position in Jazz Pharmaceuticals in Q1 2018 and held it in 9 quarters.
Boothbay Fund Management's Jazz Pharmaceuticals position peaked at $7.75M in Q4 2025.
647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.